TY - JOUR
T1 - Cavitational ultrasonic surgical aspiration for the treatment of vaginal intraepithelial neoplasia
AU - Robinson, Jubilee B.
AU - Sun, Charlotte C.
AU - Bodurka-Bevers, Diane
AU - Im, Dwight D.
AU - Rosenshein, Neil B.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2000
Y1 - 2000
N2 - Objective. The aim of this study is to determine whether cavitational ultrasonic surgical aspiration (CUSA) is effective and safe for treating vaginal intraepithelial neoplasia (VAIN). Methods. We conducted a retrospective chart review of 46 patients who were treated with CUSA for VAIN in a single gynecologic oncology practice between 1981 and 1999. Results. At initial presentation, 39% of treated patients had grade I VAIN, 20% had grade II, and 41% had grade III. The mean duration of follow-up from initial CUSA treatment was 21 months. Twenty-nine patients (63%) were initially treated with CUSA, 7 patients (15%) with laser vaporization, 7 patients (15%) with surveillance by Papanicolaou smear, 1 patient (2%) with partial vaginectomy, 1 patient (2%) with 5-fluorouracil, and 1 patient (2%) with loop excision. Patients initially treated with CUSA had a higher percentage of grade III VAIN at diagnosis (48%) than did patients initially treated with other methods (29%). A significantly greater proportion of patients initially treated with CUSA had no recurrence of VAIN (66%) compared with patients initially treated with other methods (0%) (P < 0.0001). A significantly greater proportion of patients who were treated for recurrent disease with CUSA had no further recurrence (52%) compared with patients treated for recurrent disease with other methods (9%) (P < 0.001). No patient treated with CUSA reported adverse effects; 7 patients treated with other methods reported dysuria, burning, and pain. Conclusion. These initial data suggest that CUSA is a safe and effective method for treating VAIN and may be an appropriate treatment for many patients. (C) 2000 Academic Press.
AB - Objective. The aim of this study is to determine whether cavitational ultrasonic surgical aspiration (CUSA) is effective and safe for treating vaginal intraepithelial neoplasia (VAIN). Methods. We conducted a retrospective chart review of 46 patients who were treated with CUSA for VAIN in a single gynecologic oncology practice between 1981 and 1999. Results. At initial presentation, 39% of treated patients had grade I VAIN, 20% had grade II, and 41% had grade III. The mean duration of follow-up from initial CUSA treatment was 21 months. Twenty-nine patients (63%) were initially treated with CUSA, 7 patients (15%) with laser vaporization, 7 patients (15%) with surveillance by Papanicolaou smear, 1 patient (2%) with partial vaginectomy, 1 patient (2%) with 5-fluorouracil, and 1 patient (2%) with loop excision. Patients initially treated with CUSA had a higher percentage of grade III VAIN at diagnosis (48%) than did patients initially treated with other methods (29%). A significantly greater proportion of patients initially treated with CUSA had no recurrence of VAIN (66%) compared with patients initially treated with other methods (0%) (P < 0.0001). A significantly greater proportion of patients who were treated for recurrent disease with CUSA had no further recurrence (52%) compared with patients treated for recurrent disease with other methods (9%) (P < 0.001). No patient treated with CUSA reported adverse effects; 7 patients treated with other methods reported dysuria, burning, and pain. Conclusion. These initial data suggest that CUSA is a safe and effective method for treating VAIN and may be an appropriate treatment for many patients. (C) 2000 Academic Press.
KW - CUSA
KW - Ultrasonic surgical aspiration
KW - VAIN
KW - Vaginal intraepithelial neoplasia
UR - http://www.scopus.com/inward/record.url?scp=0033847162&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033847162&partnerID=8YFLogxK
U2 - 10.1006/gyno.2000.5881
DO - 10.1006/gyno.2000.5881
M3 - Article
C2 - 10926809
AN - SCOPUS:0033847162
SN - 0090-8258
VL - 78
SP - 235
EP - 241
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 2
ER -